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Abstract
Background: Osteoarthritis is the most frequent chronic joint disease which causes pain and disability of especially
hip and knee. According to international guidelines and the Dutch general practitioners guidelines for non-
traumatic knee symptoms, acetaminophen should be the pain medication of first choice for osteoarthritis.
However, of all prescribed pain medication in general practice, 90% consists of non-steroidal anti-inflammatory
drugs compared to 10% of acetaminophen. Because general practitioners may lack evidence showing a similar
efficacy of acetaminophen and non-steroidal anti-inflammatory drugs, we present the design of a randomized
open-label trial to investigate the efficacy of a non-steroidal anti-inflammatory drug (diclofenac) compared with
acetaminophen in new consulters with knee osteoarthritis in general practice.
Methods/Design: Patients aged 45 years or older consulting their general practitioner with non-traumatic knee
pain, meeting the clinical American College of Rheumatology criteria, and with a pain severity score of 2 or higher
(on a 0-10 scale), will be randomly allocated to either diclofenac (maximum daily dose of 150 mg) or
acetaminophen (maximum daily dose of 3000 mg) for 2 weeks and, if required, an additional 1-2 weeks, with a
total follow-up period of 12 weeks. The primary outcomes are knee pain measured with a daily diary, and pain and
function measured with the Knee Injury and Osteoarthritis Outcome Score (KOOS) at baseline, and at 3, 6, 9, and
12-weeks follow-up. Secondary outcomes are patients’ perceived recovery, quality of life, medical, patient, and
productivity costs, compliance to therapy, co-interventions, and adverse reactions.
Discussion: The successful completion of this trial would lead to a better understanding of which medication
should be used in the treatment of primary care patients with mild knee osteoarthritis.
Trial registration: Dutch trial registry NTR1485.
Background
Osteoarthritis (OA) is the most frequent chronic joint
disease causing pain and disability of especially hip and
knee [1]. For most patients the general practitioner (GP)
is the initial caregiver and may provide advice and/or
pain medication. International guidelines and the Dutch
GP guidelines for treating non-traumatic knee symp-
toms recommend acetaminophen as medication of first
choice in the management of OA pain [2-4]. However, a
prospective cohort of first consulters with non-traumatic
knee symptoms in 40 Dutch general practices showed
that GPs prescribed pain medication in 27% of these
patients, 90% received non-steroidal anti-inflammatory
drugs (NSAIDs) and only 10% received acetaminophen
(Belo JN, Berger MY, Koes BW, Bierma-Zeinstra SMA:
Medical treatment and medical consumption in adults
with nontraumatic knee complaints in general practice.
Submitted).
Despite general consensus that acetaminophen has a
better safety profile, there may be insufficient evidence
for the efficacy of acetaminophen in mild OA to
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choice medication. Indeed, a systematic review of 15
randomized clinical trials (RCTs; median length 6
weeks) on the comparative effectiveness of NSAIDs ver-
sus acetaminophen in patients with hip/knee OA
reported that although acetaminophen was more effec-
tive than placebo, it provided less pain relief than
NSAIDs [5]. The efficacy of NSAIDs was especially
found in patients with moderate to severe OA, whereas
others report that the efficacy of NSAIDs and acetami-
nophen is probably similar in patients with mild OA [6].
A limitation of most RCTs is that they seldom include
patients consulting for OA (i.e. new patients) but mostly
prevalent cases already receiving treatment for OA.
Most studies included a highly selected patient group
already using a daily dose of NSAIDs and needing a
wash-out period prior to randomization [7-10]. One
trial reported (not surprisingly) that prior use of
NSAIDs predicted a better response of NSAIDs com-
pared to acetaminophen [8]. Therefore, these latter stu-
dies do not represent patients with OA in general
practice, or patients who consult their GP for the first
time with a new episode of complaints.
In view of the lack of trials comparing the efficacy of
NSAIDs with acetaminophen in new consulters with
OA, we designed an RCT to explore whether there is a
clinically relevant difference between diclofenac (an
NSAID) and acetaminophen in new patients with knee
OA in general practice. A pragmatic open-label design
was chosen to approximate GPs’ daily practice and
because patients are aware of the type of prescribed
medication. Secondary aims were to establish: 1)
whether there are predefined predictors of treatment
responders after 4-6 weeks and at 12-weeks follow-up,
and 2) the cost-effectiveness of diclofenac compared to
acetaminophen in patients with knee OA in primary
care over a 12-week period.
Presented below is the protocol of the diclofenac ver-
sus acetaminophen trial (DIPA trial), which is registered
in the Dutch trial registry (NTR1485) [11].
Methods/Design
Study design
This study is a pragmatic randomized open-label trial
with a follow-up period of 12 weeks. In this design, the
patients, researchers and GPs are not blinded for the
assigned treatment. The study is approved by the Medi-
cal Ethics Committee of the Erasmus Medical Center
(MC).
Figure 1 presents the flowchart of the study.
Inclusion/exclusion criteria
Patients are eligible for the DIPA trial (Table 1) if they
meet all four inclusion criteria: 1) consulting their GP
for a new episode of non-traumatic knee pain. A new
episode of knee pain is defined as pain presented to the
GP for the first time, or if a patient did not consult the
GP with these symptoms in the previous 3 months [12],
2) aged 45 years or older, 3) meeting the clinical Ameri-
can College of Rheumatology (ACR) criteria for OA of
the knee [13], and 4) having a pain severity of 2 or
more (on a 0-10 scale).
Patients are excluded if they are: 1) contra-indicated
for NSAID or acetaminophen use, i.e. gastrointestinal
bleedings in history or active, blood dyscrasia, bone
marrow depression (myelosuppression), serious heart
failure, serious liver or kidney disease (glomerular filtra-
tion < 30 ml/min), alcoholism, colitis ulcerosa, Crohn’s
disease, sulphite hypersensitivity, asthma, urticaria,
angioedema, nasal polyps or rhinitis after use of acetyl-
salicylic acid or other prostaglandin synthetase inhibi-
tors, or use of anti-depressive medication (SSRIs), 2)
having an arthroplasty or osteotomy of the knee on the
contralateral or unilateral side, 3) already taking NSAIDs
or acetaminophen at doses similar to or higher than the
study dose, 4) surgery or major trauma of the affected
joint within the previous 6 months, 5) myocardial
infarction or stroke in the last 6 months, and 6) oral use
of a corticosteroid.
Figure 1 Flow chart of the study.
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An academic research network of GPs in the south-west
of the Netherlands agreed to participate and to refer
patients who consult for a new episode of non-traumatic
knee pain to the DIPA trial. The GP takes the patient’s
history and performs the physical examination as part of
the usual daily care. The GP gives study information to
the patient, and sends the patient’sn a m ea n di n f o r m a -
tion regarding history taking/physical examination by
fax to the research department at Erasmus MC. Within
two days after the GP visit, patients are contacted (by
the researcher), checked for eligibility (in- and exclusion
criteria), and asked for written informed consent. Base-
line measurements and randomization then take place.
Randomization
Patients are allocated to the diclofenac or the acetami-
nophen group using a randomization list (with random
blocks of 4, 6 or 8) produced by a computer-generated
table. The GP is informed about the randomization
results and sends a prescription of the allocated medica-
tion to the patient’s pharmacy.
Interventions
Patients are randomly allocated to either diclofenac (maxi-
mum daily intake of 3 × 50 mg) or acetaminophen (maxi-
mum daily intake of 3 × 1000 mg). Both medications are
prescribed in accordance with the Dutch clinical guide-
lines for GPs for non-traumatic knee symptoms [2]. The
guideline recommends analgesics for 2 weeks and, if
required, for an additional 1-2 weeks [2]. This is in accor-
dance with the EULAR and OARSI recommendations
[3,4]. Patients in the diclofenac group with an increased
risk of gastro-intestinal problems will also receive a muco-
sal protector (e.g. omeprazol once daily, 20 mg). Patients
at increased risk of gastro-intestinal problems are 60 years
o ro l d e ra n d / o rh a v eas e r i o u sc o - m o r b i d i t y( e . g .
rheumatic disease and diabetes mellitus). Patients take
their allocated medication on demand, and can change
their medication intake when their pain level alters. This
leads to an approach that is close to usual daily care.
Outcome measures
The primary outcomes of this study are: 1) pain and
function measured with the Knee Injury and Osteoar-
thritis Outcome Score (KOOS) [14] and 2) pain assessed
with an 11-point numeric rating scale (NRS) in a diary
[15]. Secondary outcomes are: 1) patients’ perceived
pain measured every 3 weeks on the 11-point NRS [15],
2) patients’ perceived recovery measured on a 7-point
Likert scale (1 = completely recovered; 7 = worse than
ever), 3) constant and intermittent pain measured with
the Intermittent and Constant Osteoarthritis Pain
(ICOAP) questionnaire [16], 4) patients’ quality of life
assessed with the EuroQol instrument EQ-5D [17], 5)
all direct medical, patient and productivity costs mea-
sured with the PROductivity and DISease Questionnaire
(PRODISQ) [18], 6) compliance to therapy assessed in
the diary, 7) co-interventions (e.g. changes in doses of
co-medication), and 8) adverse reactions.
Questionnaires
The primary and secondary outcome measurements are
assessed with questionnaires and diaries. During the
study, patients fill out a total of 5 questionnaires (at
b a s e l i n ea n da t3 ,6 ,9 ,a n d1 2 -weeks follow-up). After
the informed consent and before randomization, the
patient fills out the baseline questionnaire. After the
baseline questionnaire, patients receive a follow-up
questionnaire every 3 weeks.
Five validated instruments are used in all 5
questionnaires.
1) The KOOS measures the functional status of patients
with knee OA [14]. The KOOS consists of 5 subscales:
pain, symptoms, activities of daily living, sport and func-
tion, and knee-related quality of life. The Dutch version
of the KOOS is validated and suitable for use in patients
with mild and moderate OA [14]. The KOOS question-
naire is an extension of the Western Ontario and
McMaster osteoarthritis index (WOMAC), and
WOMAC scores of pain and function can be calculated
from the KOOS [19-21]. The WOMAC is recommended
for use in elderly subjects with knee OA [19].
2) The measure of Intermittent and Constant Osteoar-
thritis Pain (ICOAP) identifies different types of pain
due to OA. The ICOAP is a reliable and valid to mea-
sure constant and intermittent pain [16].
3) The 11-point NRS measures the perceived level of
pain intensity (0 = no pain; 10 = worst pain ever)
[22-25]. The NRS is a valid measurement to score pain
intensity level [22].
Table 1 Inclusion and exclusion criteria of the DIPA trial.
Inclusion Criteria Exclusion Criteria
People with a new episode of
non-traumatic knee pain
Contra-indication for NSAID or
acetaminophen
Age ≥ 45 years Arthroplasty/osteotomy
Comply with the clinical ACR
criteria*
Already on NSAID or acetaminophen
use^
Pain severity scale ≥ 2o na
11-point numeric rating scale
Surgery or major trauma of affected
knee in previous 6 months
Oral corticosteroid use
Myocardial infarction or stroke in
previous 6 months
*Clinical ACR criteria: Age > 50 years, stiffness < 30 minutes, crepitus, bony
tenderness, bony enlargement, and no palpable warmth. Patients comply with
the clinical ACR criteria if they meet at least 3 of the 6 criteria.
^Excluded are those with a pre-study medication use comparable with the
study dose of diclofenac (≥ 150 mg/day) or acetaminophen (≥ 3000 mg/day)
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Page 3 of 64) The EuroQol (EQ-5D) measures quality of life. The
EuroQol is a generic questionnaire and consists of 5
dimensions: mobility, self-care, usual activities, pain/dis-
comfort, and anxiety/depression [17]. The EuroQol
allows to evaluate the cost-effectiveness of a healthcare
intervention [26,27] and can be converted into utilities
to calculate Quality Adjusted Life Years (QALYs) [28].
5) The PRODISQ measures all direct medical, patient,
and productivity costs. The PRODISQ consists of 7
modules. In the present study, only modules 1-5 are
used because these questions are related to the indivi-
dual patient, whereas modules 6 and 7 are utilized by
management. Modules 1-5 cover: 1) demography and
disease, 2) profession, working situation, and income, 3)
absence from work, 4) compensation mechanisms, and
5) productivity costs whilst at work (efficiency loss) [18].
Besides these validated questionnaires, the baseline
questionnaire addresses patient characteristics (age, gen-
der, weight, height, and social status), knee-related char-
acteristics (history and localisation of knee symptoms),
problems at work due to knee problems, and co-mor-
bidities. The four follow-up questionnaires measure
medication use, adverse reactions, medical consumption,
patients’ perceived recovery, and knee-related
characteristics.
Table 2 presents an overview of the questionnaire
items.
Pain diary
During the DIPA trial, patients fill out a diary to score
daily pain (using an 11-point NRS), medication use, and
compliance. Being a pragmatic trial, patients may
change their medication dosage when pain alters. These
alterations may be important for interpreting the results
of the trial. Therefore, information on compliance to the
allocated treatment is also collected.
Sample size
The sample size is calculated to detect clinically relevant
differences in pain and function between the two groups
(diclofenac versus acetaminophen), measured by the
KOOS during the 12-week study period. To detect a
clinically relevant difference of 10 points (15%) on the
KOOS pain score between the two treatment groups
after 12 weeks, 73 patients per group are needed (power
95%, alpha 0.05, one-sided testing). Based on an
expected 5% loss to follow, 154 patients (2 × 77) should
be included.
Statistical analyses
A l la n a l y s e sw i l lb ep e r f o r m ed on an intention-to-treat
basis, analyzing all patients in the treatment group to
which they were randomly allocated. Analysis per proto-
col will also be conducted, analyzing only those patients
that have measures on the primary outcome measure-
ment at both baseline and 12-weeks follow-up. Descrip-
tive data of baseline characteristics will be presented for
both groups to check comparability. Generalized estimat-
ing equation (GEE) analysis will be conducted to investi-
gate (longitudinally) the 2, 4, and 6 weeks effectiveness of
diclofenac compared to acetaminophen for pain assessed
with the diary. Differences between the two groups over
Table 2 Overview of questionnaire items.
0 weeks
B.Q.
3 weeks
F.U.Q.
6 weeks
F.U.Q.
9 weeks
F.U.Q.
12 weeks
F.Q.
Diary
Demographics
Age, gender, weight, height, and social status X
Outcome measures
Pain score (NRS) XXXX X X
Pain score (KOOS) XXXX X
Function score (KOOS) XXXX X
Perceived recovery XXXX X
Constant pain, and pain that comes and goes (ICOAP) XXXX X
Quality of life (EuroQol) XXXX X
Direct medical, patient, and productivity costs (PRODISQ) X
Compliance X
Adverse reactions XXX X
Other outcomes
Knee-related characteristics (History, duration, and localisation) X
Co-morbidities X
Medication use XXX X X
Medical consumption (Visit to GP, medical specialist, physical therapist, etc.) XXX X
B.Q. = Baseline Questionnaire; F.U.Q. = Follow-up Questionnaire; F.Q. = Final Questionnaire; KOOS = Knee Osteoarthritis Outcome Score; NRS = Numeric Rating
Scale; ICOAP = Intermittent and Constant OsteoArthritis Pain; PRODISQ = PROductivity and DISease Questionnaire
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Page 4 of 6the 12-week follow-up will also be assessed with GEE.
The outcome variables are pain (measured with the
NRS), and pain and function (assessed with the KOOS).
Using GEE, the correlation of multiple measurements
within one patient is taken into account [29].
To detect predictive variables for treatment respon-
ders at 12-weeks follow-up multivariate regression ana-
lyses will be used. Treatment response is defined based
on the OMERACT-OARSI responder criteria [30,31] as
a high improvement in pain or function of ≥ 50%, or an
improvement on pain ≥ 20%, and/or function ≥ 20%.
In addition, a cost-utility analysis will be performed
that expresses health improvements in QALYs assessed
with the EuroQol. If the course of OA (and its related
costs) appears to fluctuate (particularly if the difference
between treatment arms is not stable over time), an
additional modeling study using a Markov model will be
performed. Statistical methods will be used to describe
uncertainty in costs and effects estimates based on
patient data. A 95% confidence interval for the cost-uti-
lity ratio will be calculated and an acceptability curve
presented. In case of a modeling study, a probabilistic
sensitivity analysis will be performed.
Discussion
Recruitment of the 154 patients has started and will end
in 2010. We expect to report study results in 2011. The
successful completion of this trial would lead to a better
understanding of which medication should be used in
the treatment of primary care patients with mild knee
osteoarthritis.
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